NANTES, France & PARIS--(BUSINESS WIRE)--Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, will present in an oral session preclinical studies results for Effi-DEM, a new generation checkpoint inhibitor targeting Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM), at the ICI (Immune Checkpoint Inhibitors) conference (Munich, November 16th to 18th, 2016).
Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International scientific collaborations, will present and comment all of the data from its preclinical studies conducted with Effi-DEM both in vivo and in vitro and in various cancer models.
Effi-DEM, a new generation checkpoint inhibitor specifically targeting the SIRP- α receptor on the strategic SIRP-α/CD47 pathway, has the potential to transform suppressor myeloid and macrophage cells in non-suppressive cells, thereby inducing a reactivation of the immune response, an anti-tumor impact and an immune memory.
SIRP-α is a receptor strongly expressed by Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM) and its ligand is CD47. Suppressor immune cells MDSC and TAM play a key role in tumor growth of inflammatory cancers.
Effi-DEM has shown to be effective in various aggressive cancer models with encouraging preclinical results, both in monotherapy and in therapeutic combinations with anti-PD-L1 (checkpoint inhibitors) and anti-CD137 (4-1BB), activators of the T-cell response. Significant efficacy and survival increase data were demonstrated in hepatocarcinoma, melanoma and triple negative breast cancer models.
“These preclinical results validate the therapeutic potential of our new generation checkpoint inhibitor Effi-DEM in immuno-oncology, and show how the product enhances immune response by targeting novel checkpoint SIRP-α/CD 47 pathway. OSE Immunotherapeutics is at the forefront of this new immuno-oncology area and clearly focuses in developing such an innovative product”, commented Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics.
Details of the presentation are as follows:
Title: Selective Targeting of The SIRP-α Immune Checkpoint To Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control Polarization Of Human Macrophages
Date/Time: Thursday, November 17, 2016, 10:30am CET
Location:
Maritim Hotel München, Goethestraße 7, 80336 Munich, Germany
These preclinical data will also be presented in an abstract at the Annual World Gene Convention-2016 (WGC-2016), which will be held during November 3-5, 2016 in Shanghai, China.
About ICI (IMMUNE CHECKPOINT INHIBITORS) EUROPE
ICI Europe
is a forum dedicated to immune checkpoint inhibitors. It focuses
specifically on the preclinical, translational and clinical challenges
that drug developers face in advancing more checkpoint inhibitors onto
the market. Combining data driven case studies with interactive
experience sharing sessions, its program provides cutting edge insights
into novel checkpoint pathways, more predictive preclinical models, the
optimal combination strategies, patient stratification biomarkers and
emerging clinical trial data.
ABOUT WGC (ANNUAL WORLD GENE CONVENTION)
WGC-2016 features a
very strong technical program, mainly focused on breakthroughs in DNA
and RNA research, advances of genomics & genetics, the frontier research
of life sciences. It aims to provide a platform for all experts from
academia, industry and national labs to discuss latest hot researches
and achievements.
ABOUT OSE IMMUNOTHERAPEUTICS
Our ambition is to become
a world leader in activation and regulation immunotherapies
OSE Immunotherapeutics is a biotechnology company led by world-class
immunologists and focused on the development of innovative
immunotherapies for immune activation and regulation in the fields of
immuno-oncology, auto-immune diseases and transplantation.
The
company has a balanced portfolio of first-in-class products with a
diversified risk profile ranging from clinical phase 3 registration
trials to R&D:
- Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan Status in the US - registration expected in 2019 - a Phase 2 with Tedopi® in combination with a checkpoint inhibitor in NSCLC is considered in 2017 - the product is also considered in other cancer indications.
- FR104, CD28-antagonist in immunotherapy - Phase 1 trial completed - targets autoimmune diseases and transplantation - licensed to J&J to pursue clinical development
- Effi-7, interleukin receptor 7 antagonist - in preclinical development for inflammatory bowel diseases and other autoimmune diseases
- Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-α receptor on the strategic SIRP-α/CD47 pathway - in preclinical development for immuno-oncology
- R&D: candidates targeting new receptors in immuno-oncology
The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players, such as the one signed for FR104 with the J&J Group.
Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **.
There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales upper $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.
*Citi Research Equity
**BCC Research
More information: http://ose-immuno.com
Click and follow us on Twitter and Linkedln
Forward-looking statements
This press release
contains express or implied information and statements that might be
deemed forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based
upon certain assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of historical
trends, current economic and industry conditions, expected future
developments and other factors they believe to be appropriate.
These
forward-looking statements include statements typically using
conditional and containing verbs such as “expect”, “anticipate”,
“believe”, “target”, “plan”, or “estimate”, their declensions and
conjugations and words of similar import.
Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE Immunotherapeutics’
shareholders and other investors are cautioned that the completion of
such expectations is by nature subject to various risks, known or not,
and uncertainties which are difficult to predict and generally beyond
the control of OSE Immunotherapeutics. These risks could cause actual
results and developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by OSE
Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance.
This press release includes only
summary information and should be read with the OSE Immunotherapeutics
Reference Document filed with the AMF on 8 June 2016 under the number
R.16-052, the consolidated financial statements and the management
report for the fiscal year 2015, as well as the Merger Document
registered with the AMF on 26 April 2016 under number E.16-026, all
available on the OSE Immunotherapeutics’ website.
Other than as
required by applicable law, OSE Immunotherapeutics issues this press
release at the date hereof and does not undertake any obligation to
update or revise the forward-looking information or statements.
